NasdaqCM - Nasdaq Real Time Price • USD
Atossa Therapeutics, Inc. (ATOS)
As of 12:41 PM EDT. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
31,377.0000
--
27,691.0000
20,521.0000
14,607.0000
Operating Income
-31,377.0000
--
-27,691.0000
-20,521.0000
-14,607.0000
Net Non Operating Interest Income Expense
4,343.0000
--
877.0000
6.0000
-938.7940
Other Income Expense
-3,060.0000
--
-146.0000
-91.0000
-3,221.0000
Pretax Income
-30,094.0000
--
-26,960.0000
-20,606.0000
-17,828.0000
Net Income Common Stockholders
-30,094.0000
--
-26,960.0000
-20,606.0000
-22,331.0000
Diluted NI Available to Com Stockholders
-30,094.0000
--
-26,960.0000
-20,606.0000
-22,331.0000
Basic EPS
-0.24
-0.24
-0.21
-0.18
-1.97
Diluted EPS
-0.24
-0.24
-0.21
-0.18
-1.97
Basic Average Shares
126,081.6020
126,081.6020
126,624.1100
116,950.0000
11,309.0000
Diluted Average Shares
126,081.6020
126,081.6020
126,624.1100
116,950.0000
11,309.0000
Total Operating Income as Reported
-31,377.0000
--
-27,691.0000
-20,521.0000
-14,607.0000
Total Expenses
31,377.0000
--
27,691.0000
20,521.0000
14,607.0000
Net Income from Continuing & Discontinued Operation
-30,094.0000
--
-26,960.0000
-20,606.0000
-17,828.0000
Normalized Income
-27,104.0000
--
-26,960.0000
-20,606.0000
-14,556.0000
Interest Income
4,343.0000
--
877.0000
6.0000
--
Net Interest Income
4,343.0000
--
877.0000
6.0000
-938.7940
EBIT
-31,377.0000
--
-27,691.0000
-20,521.0000
-14,607.0000
EBITDA
-31,354.0000
--
-27,683.0000
-20,498.0000
-14,560.0000
Reconciled Depreciation
23.0000
--
8.0000
23.0000
47.0000
Net Income from Continuing Operation Net Minority Interest
-30,094.0000
--
-26,960.0000
-20,606.0000
-17,828.0000
Total Unusual Items Excluding Goodwill
-2,990.0000
--
--
--
-3,272.0000
Total Unusual Items
-2,990.0000
--
--
--
-3,272.0000
Normalized EBITDA
-28,364.0000
--
-27,683.0000
-20,498.0000
-11,288.0000
12/31/2020 - 11/8/2012
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
OCGN Ocugen, Inc.
1.8950
+11.47%
TNXP Tonix Pharmaceuticals Holding Corp.
0.1820
+1.11%
SLS SELLAS Life Sciences Group, Inc.
1.3899
+1.45%
CTXR Citius Pharmaceuticals, Inc.
0.6545
-4.81%
JAGX Jaguar Health, Inc.
0.2657
-3.36%
VXRT Vaxart, Inc.
0.9253
+7.01%
AKBA Akebia Therapeutics, Inc.
1.1800
-4.08%
CADL Candel Therapeutics, Inc.
11.57
+8.13%
RVPH Reviva Pharmaceuticals Holdings, Inc.
1.6599
-9.05%
INO Inovio Pharmaceuticals, Inc.
12.72
+11.38%